Neal D. Shore, MD, FACS

Videos

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

Neal D. Shore, MD, FACS, Talks Findings From the Phase 3 HERO Trial

Articles

The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.

Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial

Podcasts

In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.

Upfront Chemotherapy in Prostate Cancer

In this article, we review recent advances in the discovery of prostate cancer biomarkers, their integration into clinical practice, and implications for improving clinical management of the disease.

Author | Neal D. Shore, MD, FACS

Articles

New content coming soon, please check back later.